AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20724431 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. CYC and prednisolone in disease controls
Number of subjects: 12
Study 20724431 — intervention group
Group type: EXPERIMENTAL
Intervention: EPC responders (CYC group)
Number of subjects: 12
Study 20724431 — intervention group
Group type: EXPERIMENTAL
Intervention: EPC non-responders (CYC group)
Number of subjects: 12
Study 20724431 — intervention group
Group type: EXPERIMENTAL
Intervention: CYC group
Number of subjects: 12
Study 19005196 — intervention group
Group type: EXPERIMENTAL
Intervention: Active stimulation of the subthalamic nucleus
Number of subjects: 8
Study 19005196 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 8
Study 15728070 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral clonidine 100 microg
Number of subjects: 61
Study 15728070 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study 12637258 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained hyperglycemia (glucose concentration approximately 7.0 mM)
Number of subjects: 31
Study 12637258 — intervention group
Group type: EXPERIMENTAL
Intervention: Postprandial glucose profile (glucose peaked at 11.2 ± 0.5 mmol/l)
Number of subjects: 31
Study 12637258 — intervention group
Group type: COMPARATOR
Intervention: Euglycemia (glucose clamped at approximately 5.3 mM)
Number of subjects: 31
Study 12637258 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained hyperglycemia and postprandial profile
Number of subjects: 31
Study 10791184 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy
Number of subjects: 70
Study 10791184 — intervention group
Group type: COMPARATOR
Intervention: Open cholecystectomy
Number of subjects: 70
Study 10791184 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Laparoscopic and Open)
Number of subjects: 70
Study 8852389 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg sematilide HCl intravenous infusion over 30 minutes
Number of subjects: 22
Study 8852389 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg sematilide HCl tablet
Number of subjects: 22
Study 8852389 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous and oral administration of sematilide HCl
Number of subjects: 22
Study 1399032 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-carotene (20 mg daily for 14 weeks)
Number of subjects: 123
Study 1399032 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 123
Study 1399032 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-carotene (after intervention)
Number of subjects: 123
Study 3893014 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam 0.08 mg/kg
Number of subjects: 30
Study 3893014 — intervention group
Group type: COMPARATOR
Intervention: d‐tubocurarine 0.05 mg/kg
Number of subjects: 30
Study 31427688 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning (RIPC)
Number of subjects: 222
Study 31427688 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard preventive measures)
Number of subjects: 222
Study 30265691 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic treatment (daily multi-strain capsule containing Lactobacillus acidophilus NCFM, Lactobacillus paracasei Lpc-37, Bifidobacterium lactis Bi-07, Bifidobacterium lactis B1-04)
Number of subjects: 0
Study 30265691 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 27215976 — intervention group
Group type: EXPERIMENTAL
Intervention: Lurasidone monotherapy (20-60 mg/day or 80-120 mg/day)
Number of subjects: 825
Study 27215976 — intervention group
Group type: EXPERIMENTAL
Intervention: Lurasidone adjunctive therapy (20-120 mg/day)
Number of subjects: 825
Study 27215976 — intervention group
Group type: EXPERIMENTAL
Intervention: Lurasidone monotherapy
Number of subjects: 825
Study 27215976 — intervention group
Group type: EXPERIMENTAL
Intervention: Lurasidone adjunctive therapy
Number of subjects: 825
Study 25002297 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete set of 60 cases
Number of subjects: 0
Study 25002297 — intervention group
Group type: EXPERIMENTAL
Intervention: Consensus set with agreement among experienced graders
Number of subjects: 0
Study 25002297 — intervention group
Group type: COMPARATOR
Intervention: Consensus set compared to complete set
Number of subjects: 0
Study 22588803 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai chi classes
Number of subjects: 100
Study 22588803 — intervention group
Group type: COMPARATOR
Intervention: Time-matched education control
Number of subjects: 100
Study 20211295 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous early endothelial progenitor cells (EPCs)
Number of subjects: 99
Study 20211295 — intervention group
Group type: EXPERIMENTAL
Intervention: E-CMMs transfected with human endothelial nitric oxide synthase
Number of subjects: 99
Study 20211295 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Plasma-Lyte A)
Number of subjects: 99
Study 18569274 — intervention group
Group type: EXPERIMENTAL
Intervention: Silica gel
Number of subjects: 74
Study 18569274 — intervention group
Group type: COMPARATOR
Intervention: Acyclovir cream
Number of subjects: 74
Study 15759526 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower leg casting plus injections with botulinum toxin (group III)
Number of subjects: 35
Study 15759526 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower leg casting plus injections with saline (group II)
Number of subjects: 35
Study 15759526 — intervention group
Group type: COMPARATOR
Intervention: Current physical treatment (group I)
Number of subjects: 35
Study 11831530 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral intervention designed to improve the attitude and behavior of stockpeople toward cows
Number of subjects: 123
Study 11831530 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral intervention
Number of subjects: 123
Study 11831530 — intervention group
Group type: COMPARATOR
Intervention: Control treatment (no intervention)
Number of subjects: 123
Study 9920138 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) treatment at supraphysiological dosages (up to 8 IU/m2/d) for 4 years in the dose-response study.
Number of subjects: 87
Study 9920138 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) treatment at a total dose of 6 IU/m2/d with low-dose ethinyl estradiol (50 ng/kg/d orally) in once-daily (OD) and twice-daily (BID) injection regimens for 2 years in the frequency-response study.
Number of subjects: 87
Study 9920138 — intervention group
Group type: COMPARATOR
Intervention: Comparison with healthy Dutch control subjects in the dose-response study.
Number of subjects: 87
Study 9920138 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing GH dosage in the dose-response study.
Number of subjects: 87
Study 9920138 — intervention group
Group type: EXPERIMENTAL
Intervention: GH treatment at supraphysiological dosages.
Number of subjects: 87
Study 7755523 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Analytical Therapy
Number of subjects: 30
Study 7755523 — intervention group
Group type: COMPARATOR
Intervention: Educational Behavioral Treatment
Number of subjects: 30
Study 2271377 — intervention group
Group type: EXPERIMENTAL
Intervention: Apomorphine hydrochloride (0.5, 1, and 2 micrograms kg‐1 s.c.)
Number of subjects: 8
Study 2271377 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 355663 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclobenzaprine hydrochloride (10 mg three times a day)
Number of subjects: 32
Study 355663 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam (5 mg three times a day)
Number of subjects: 32
Study 355663 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 31721005 — intervention group
Group type: EXPERIMENTAL
Intervention: Barriers to engaging ethnic minorities and families receiving social services
Number of subjects: 0
Study 31721005 — intervention group
Group type: EXPERIMENTAL
Intervention: Facilitators for engagement
Number of subjects: 0
Study 31721005 — intervention group
Group type: EXPERIMENTAL
Intervention: Organizational culture
Number of subjects: 0
Study 31009099 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized controlled trials (n=45)
Number of subjects: 100
Study 31009099 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic reviews (n=30)
Number of subjects: 100
Study 31009099 — intervention group
Group type: EXPERIMENTAL
Intervention: Outcome studies of root canal treatment (n=35)
Number of subjects: 100
Study 31009099 — intervention group
Group type: EXPERIMENTAL
Intervention: Articles published in the Journal of Endodontics (n=70)
Number of subjects: 100
Study 31009099 — intervention group
Group type: EXPERIMENTAL
Intervention: Articles published in the International Endodontic Journal (n=27)
Number of subjects: 100
Study 31009099 — intervention group
Group type: EXPERIMENTAL
Intervention: Meta-analysis (n=23)
Number of subjects: 100
Study 31009099 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic review (n=23)
Number of subjects: 100
Study 28385185 — intervention group
Group type: EXPERIMENTAL
Intervention: BoNT/A (BOTOX®, Allergan) tri-annually
Number of subjects: 38
Study 28385185 — intervention group
Group type: COMPARATOR
Intervention: BoNT/A (BOTOX®, Allergan) annually
Number of subjects: 38
Study 28385185 — intervention group
Group type: EXPERIMENTAL
Intervention: BoNT/A (BOTOX®, Allergan) tri-annually and annually
Number of subjects: 38
Study 28385185 — intervention group
Group type: EXPERIMENTAL
Intervention: Caucasian patients treated with BoNT/A
Number of subjects: 38
Study 25616430 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboplatin AUC of 6 on day 1 and nab-paclitaxel 300 mg/m(2) on day 1 every 3 weeks
Number of subjects: 0
Study 25616430 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboplatin AUC of 6 on day 1 and nab-paclitaxel 100 mg/m(2) on days 1, 8, and 15 every 21 days
Number of subjects: 0
Study 25616430 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 24063840 — intervention group
Group type: EXPERIMENTAL
Intervention: Resolute zotarolimus-eluting stent (R-ZES)
Number of subjects: 256
Study 24063840 — intervention group
Group type: COMPARATOR
Intervention: Sirolimus-eluting stent (SES)
Number of subjects: 256
Study 24063840 — intervention group
Group type: COMPARATOR
Intervention: Both R-ZES and SES
Number of subjects: 256
Study 20410682 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based lifestyle intervention (31 specific interventions including individual counselling and group sessions)
Number of subjects: 549
Study 20410682 — intervention group
Group type: COMPARATOR
Intervention: Control group (7 newsletters providing health information and results of health checkups)
Number of subjects: 549
Study 18697848 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral health counseling and dental exam at baseline, followed by randomization and follow-up visits at 9, 12, 18, 24, 30, and 36 months postpartum.
Number of subjects: 556
Study 18697848 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher annual household income
Number of subjects: 556
Study 18697848 — intervention group
Group type: EXPERIMENTAL
Intervention: Mexican/Mexican-American ethnicity
Number of subjects: 556
Study 15668329 — intervention group
Group type: EXPERIMENTAL
Intervention: Adult open-bite patients
Number of subjects: 39
Study 15668329 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-pubertal open-bite patients
Number of subjects: 39
Study 15668329 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 39
Study 12836808 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketotifen fumarate 0.025% ophthalmic solution
Number of subjects: 66
Study 12836808 — intervention group
Group type: COMPARATOR
Intervention: Olopatadine hydrochloride 0.1% ophthalmic solution
Number of subjects: 66
Study 12836808 — intervention group
Group type: EXPERIMENTAL
Intervention: Both drugs
Number of subjects: 66
Study 10818329 — intervention group
Group type: EXPERIMENTAL
Intervention: Right internal jugular vein (RIJV) cannulation using the landmark approach (Group 1)
Number of subjects: 120
Study 10818329 — intervention group
Group type: EXPERIMENTAL
Intervention: Right internal jugular vein (RIJV) cannulation using surface ultrasound (Group 2)
Number of subjects: 120
Study 10818329 — intervention group
Group type: COMPARATOR
Intervention: Left internal jugular vein (LIJV) cannulation using the landmark approach (Group 3)
Number of subjects: 120
Study 10818329 — intervention group
Group type: COMPARATOR
Intervention: Left internal jugular vein (LIJV) cannulation using surface ultrasound (Group 4)
Number of subjects: 120
Study 8852909 — intervention group
Group type: EXPERIMENTAL
Intervention: PRP-T conjugate vaccine
Number of subjects: 0
Study 8852909 — intervention group
Group type: COMPARATOR
Intervention: Diphtheria-tetanus-pertussis vaccine
Number of subjects: 0
Study 1906248 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 70
Study 1906248 — intervention group
Group type: COMPARATOR
Intervention: Methohexitone
Number of subjects: 70
Study 6872409 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (240 mg daily)
Number of subjects: 22
Study 6872409 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol (300 mg daily)
Number of subjects: 22
Study 6872409 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 29087035 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurocognitive assessment battery (including Executive Function, Processing Speed, and Verbal Memory)
Number of subjects: 49
Study 29087035 — intervention group
Group type: EXPERIMENTAL
Intervention: Processing Speed tests
Number of subjects: 49
Study 29087035 — intervention group
Group type: EXPERIMENTAL
Intervention: Executive Function tests
Number of subjects: 49
Study 29087035 — intervention group
Group type: EXPERIMENTAL
Intervention: Memory performance
Number of subjects: 49
Study 29087035 — intervention group
Group type: EXPERIMENTAL
Intervention: Declines in Executive Function
Number of subjects: 49
Study 27922569 — intervention group
Group type: EXPERIMENTAL
Intervention: Paper cognitive aid (CA)
Number of subjects: 139
Study 27922569 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic cognitive aid (CA)
Number of subjects: 139
Study 27922569 — intervention group
Group type: COMPARATOR
Intervention: Control (memory alone)
Number of subjects: 139
Study 25231808 — intervention group
Group type: EXPERIMENTAL
Intervention: Newborn care education (50-minute session using video, verbal education, demonstration and practice)
Number of subjects: 53
Study 25231808 — intervention group
Group type: COMPARATOR
Intervention: Control group (no education)
Number of subjects: 53
Study 23557224 — intervention group
Group type: EXPERIMENTAL
Intervention: PRK + 0.02% mitomycin C (MMC) for 20 seconds
Number of subjects: 27
Study 23557224 — intervention group
Group type: COMPARATOR
Intervention: PRK
Number of subjects: 27
Study 23557224 — intervention group
Group type: EXPERIMENTAL
Intervention: Total sample preoperative and postoperative results
Number of subjects: 27
Study 23557224 — intervention group
Group type: EXPERIMENTAL
Intervention: Corneal sensation
Number of subjects: 27
Study 20863238 — intervention group
Group type: EXPERIMENTAL
Intervention: Efavirenz-based antiretroviral therapy
Number of subjects: 196
Study 18936218 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg/d AA + (n‐3) LCPUFA (320 mg/d DHA, 80 mg/d eicosapentaenoic acid, 80 mg/d other (n‐3) fatty acids)
Number of subjects: 33
Study 18936218 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg/d AA + (n‐3) LCPUFA (320 mg/d DHA, 80 mg/d eicosapentaenoic acid, 80 mg/d other (n‐3) fatty acids)
Number of subjects: 33
Study 18936218 — intervention group
Group type: COMPARATOR
Intervention: (n‐3) LCPUFA alone (320 mg/d DHA, 80 mg/d eicosapentaenoic acid, 80 mg/d other (n‐3) fatty acids)
Number of subjects: 33
Study 16827739 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomization procedure reporting
Number of subjects: 43
Study 16827739 — intervention group
Group type: EXPERIMENTAL
Intervention: Blinding in outcome assessment
Number of subjects: 43
Study 16827739 — intervention group
Group type: EXPERIMENTAL
Intervention: Handling of subject withdrawals
Number of subjects: 43
Study 16827739 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall quality scores
Number of subjects: 43
Study 12756020 — intervention group
Group type: EXPERIMENTAL
Intervention: VAD combined with fludarabine (25 mg/m2/day i.v. for 5 days)
Number of subjects: 19
Study 12756020 — intervention group
Group type: COMPARATOR
Intervention: VAD (control group)
Number of subjects: 19
Study 12756020 — intervention group
Group type: EXPERIMENTAL
Intervention: VAD combined with fludarabine
Number of subjects: 19
Study 10963641 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide, methotrexate, and fluorouracil (CMF) adjuvant therapy
Number of subjects: 281
Study 10963641 — intervention group
Group type: COMPARATOR
Intervention: No further treatment after surgery +/‐ radiotherapy (Control)
Number of subjects: 281
Study 8797150 — intervention group
Group type: EXPERIMENTAL
Intervention: L-arginine 20 g/day
Number of subjects: 26
Study 8797150 — intervention group
Group type: EXPERIMENTAL
Intervention: D-arginine 10 microM
Number of subjects: 26
Study 8797150 — intervention group
Group type: EXPERIMENTAL
Intervention: L-arginine 10 microM
Number of subjects: 26
Study 8797150 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 1508620 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulus duration of 50 msec with ISOIs of 20-50 msec
Number of subjects: 5
Study 1508620 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulus duration of 10 msec or less
Number of subjects: 5
Study 1508620 — intervention group
Group type: EXPERIMENTAL
Intervention: Various ISOIs (0, 2, 4, 6, 8, 10, 15, 20, 50, or 70 msec)
Number of subjects: 5
Study 1508620 — intervention group
Group type: EXPERIMENTAL
Intervention: Duration x ISOI interaction
Number of subjects: 5
Study 1508620 — intervention group
Group type: EXPERIMENTAL
Intervention: Separation x duration x ISOI interaction
Number of subjects: 5
Study 6234341 — intervention group
Group type: EXPERIMENTAL
Intervention: Group I - 5.25% NaOCl
Number of subjects: 0
Study 6234341 — intervention group
Group type: COMPARATOR
Intervention: Group II - 17% EDTA followed by 5.25% NaOCl
Number of subjects: 0
Study 30430961 — intervention group
Group type: EXPERIMENTAL
Intervention: Prediction model using data up to week 1
Number of subjects: 2011
Study 30430961 — intervention group
Group type: EXPERIMENTAL
Intervention: Prediction model using data up to week 3
Number of subjects: 2011
Study 30430961 — intervention group
Group type: EXPERIMENTAL
Intervention: Remission at week 9
Number of subjects: 2011
Study 30547481 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-management education programme
Number of subjects: 40
Study 30547481 — intervention group
Group type: EXPERIMENTAL
Intervention: Health literacy questionnaire
Number of subjects: 40
Study 30547481 — intervention group
Group type: EXPERIMENTAL
Intervention: Socio-anthropological perspective
Number of subjects: 40
Study 26582396 — intervention group
Group type: EXPERIMENTAL
Intervention: H. pylori treatment (n=87)
Number of subjects: 169
Study 26582396 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=82)
Number of subjects: 169
Study 25093169 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensified and modulated adjuvant treatment with a minimum dose of 64.8 Gy, higher doses of 70.2 Gy (85.4%), pelvic lymph nodes irradiation (57.7%), and/or hormonal therapy (69.1%)
Number of subjects: 123
Study 22435948 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive therapy
Number of subjects: 621
Study 22435948 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 621
Study 21294424 — intervention group
Group type: EXPERIMENTAL
Intervention: Home rehabilitation program
Number of subjects: 58
Study 21294424 — intervention group
Group type: COMPARATOR
Intervention: Conventional hospital care
Number of subjects: 58
Study 18005604 — intervention group
Group type: EXPERIMENTAL
Intervention: Patellar resurfacing
Number of subjects: 60
Study 18005604 — intervention group
Group type: COMPARATOR
Intervention: Patellar reshaping
Number of subjects: 60
Study 18005604 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 60
Study 16186073 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral hormone replacement therapy (HRT)
Number of subjects: 140
Study 16186073 — intervention group
Group type: COMPARATOR
Intervention: Transdermal hormone replacement therapy (HRT)
Number of subjects: 140
Study 16186073 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 140
Study 14520226 — intervention group
Group type: EXPERIMENTAL
Intervention: Postprandial blood glucose monitoring
Number of subjects: 61
Study 14520226 — intervention group
Group type: COMPARATOR
Intervention: Preprandial blood glucose monitoring
Number of subjects: 61
Study 10652167 — intervention group
Group type: EXPERIMENTAL
Intervention: Eyecor Camera System
Number of subjects: 127
Study 10652167 — intervention group
Group type: COMPARATOR
Intervention: Standard vision screening techniques
Number of subjects: 127
Study 9074912 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromocryptine
Number of subjects: 19
Study 9074912 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisuride
Number of subjects: 19
Study 1916980 — intervention group
Group type: EXPERIMENTAL
Intervention: Intercapsular technique
Number of subjects: 76
Study 1916980 — intervention group
Group type: COMPARATOR
Intervention: Endocapsular technique
Number of subjects: 76
Study 6624767 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily home glucose monitoring
Number of subjects: 0
Study 6624767 — intervention group
Group type: COMPARATOR
Intervention: Weekly venipuncture protocol
Number of subjects: 0
Study 30621659 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium hydroxide cement associated with HVGIC
Number of subjects: 108
Study 30621659 — intervention group
Group type: COMPARATOR
Intervention: HVGIC restoration
Number of subjects: 108
Study 30621659 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 108
Study 29264836 — intervention group
Group type: EXPERIMENTAL
Intervention: Vorinostat (VOR) 200 mg po alternating 7 days on then 7 days off throughout a 28-day cycle with Bevacizumab (BEV) 10 mg/kg iv every 2 weeks and daily Temozolomide (TMZ) 50 mg/m² po daily
Number of subjects: 48
Study 29264836 — intervention group
Group type: EXPERIMENTAL
Intervention: Vorinostat (VOR) 400 mg po alternating 7 days on then 7 days off throughout a 28-day cycle with Bevacizumab (BEV) 10 mg/kg iv every 2 weeks and daily Temozolomide (TMZ) 50 mg/m² po daily
Number of subjects: 48